We are international
Donate
TEXT SIZE   


Open Thalomid (thalidomide) Clinical Trials
05.01.08

OPEN TRIALS (RECRUITING PATIENTS)
(for a complete list of thalidomide trials, go to the National Cancer Institute's site clinicaltrials.gov
.

PHASE I/II

US TRIALS

  • Tandem High-Dose Therapy With Melphalan & Total Marrow Irradiation (TMI) With PBPC Support & Dexamethasone/Thalidomide Maintenance (CHNMC-04064)
    Duarte, CA

  • Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells (MSGCC-0610-GCC)
    multicenter

FOREIGN TRIALS

  • A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients (MM2005)
    Italy - multicenter

PHASE II

US TRIALS

  • A Phase II Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone(MEL-VTD) and Autologous Transplantation for Patients Relapsing or Progressing After Tandem Transplantation (UARK 2007-01)
    Little Rock, AR

  • A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance (UARK 2006-66)
    Little Rock, AR

  • A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (UARK 2003-18)
    Little Rock, AR

  • Phase II Study of Rapidly Recycled High Dose DTPACE (HD-DTPACE) for Untreated or Previously Treated, High-Risk Multiple Myeloma (MM) (UARK 2006-32)
    Little Rock, AR

  • Phase II Study of VDT (VELCADE, Doxil® and Thalidomide) as Frontline Therapy for Patients With Previously Untreated Multiple Myeloma (MM) (RPCI-I-59105)
    Buffalo, NY

  • Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma [Not yet recruiting] (RV-MM-PI-0132)
    New York, NY

  • A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma (RV-MM-PI-238)
    New York, NY

  • Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma (MSKCC-06067)
    New York, NY

  • Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone a Previous Autologous or Syngeneic Bone Marrow or Stem Cell Transplant for Multiple Myeloma (FHCRC-1767.00)
    Seattle, WA - multicenter

  • A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study) (SWOG-S0115)
    multicenter

  • A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients (FHCRC-2123.00)
    multicenter

FOREIGN TRIALS

  • A Phase 2, Randomized Study of VELCADE® (Bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (Bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who Are Candidates for Autologous Transplantation [Not yet recruiting] (26866138-MMY-2043)
    Vienna, Austria

  • Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma (T-CID)
    Bonn, Germany

  • PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma (KMM55)
    Incheon, South Korea

  • Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM (KMM51)
    Seoul, South Korea

  • Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients (KMM53)
    South Korea

  • An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma
    multicenter

PHASE II/III

FOREIGN TRIALS

  • International, Multi-Center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-Alpha Versus Interferon-Alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma (01-002-0601)
    Vienna, Austria

PHASE III

US TRIALS

  • A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone (2006-05)
    Little Rock, AR

  • A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients (UARK 2006-15)
    Little Rock, AR

  • Tandem Autotransplantation for Multiple Myeloma Patients With Less Than 12 Months of Preceding Therapy, Incorporating Bortezomib With the Transplant Chemotherapy and During Maintenance (25009)
    Salt Lake City, UT

  • A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma (ECOG-NCIC-JMY10)
    multicenter

  • A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma (MAYO-MC0289)
    multicenter

  • Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone (C05009)
    multicenter

  • An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimidâ„¢) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy (ECOG-E1A06)
    multicenter

  • A Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m + Amifostine With Melphalan 200mg/m + Amifostine, Followed by Further Dose Intensification and Maintenance Therapy (FHCRC-2004.00)
    multicenter

FOREIGN TRIALS

  • A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma (ECOG-NCIC-JMY10)
    Canada - multicenter

  • GEM05 for Patients With Multiple Myeloma Under 65 Years (2005-001110-41)
    Spain - multicenter

  • GEM05 for Patients With Multiple Myeloma More than 65 Years (2005-001111-21)
    Spain - multicenter

  • Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma (NMSG 17/07)
    multicenter

  • A Randomized Controlled Study of Velcade (Bortezomib) Plus Thalidomide Plus Dexamethasone Compared to Thalidomide Plus Dexamethasone for the Treatment of Myeloma Patients Progressing or Relapsing After Autologous Transplantation (EBMT-CLWP: 42206611)
    multicenter

PHASE IV

FOREIGN TRIALS

  • Thalidomide-Cyclophosphamide-Dexamethasone (TaCyDex) in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/ Thalidomide-Cyclophosphamide-Dexamethasone (TaCyDex)in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma (TaCyDexVMP7)
    Spain - multicenter


 related articles